Evidence map›Paper›PMID 41472237›Full record

ArticleViruses2025

Accessing HIV Care to Irregular Migrants in Israel, 2019-2024.

Tali Wagner, Zohar Mor, Yaakov Dickstein, Dan Turner, Eynat Kedem, Itzchak Levy, Anat Wieder-Finesod, Hila Elinav, Ibrahim Nasser Eddin, Karen Olshtain-Pops and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tali WagnerDepartment of Tuberculosis and AIDS, Ministry of Health, Jerusalem 9438317, Israel.
Zohar MorDepartment of Tuberculosis and AIDS, Ministry of Health, Jerusalem 9438317, Israel.ORCID 0000-0002-3458-1611
Yaakov DicksteinInfectious Disease Unit and HIV Clinics, Rambam Health Care Campus, Haifa 3109601, Israel.
Dan TurnerFaculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.
Eynat KedemImmunology Unit, Rambam Health Care Campus, Haifa 3109601, Israel.
Itzchak LevyFaculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0003-4716-1293
Anat Wieder-FinesodFaculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.
Hila ElinavFaculty of Medicine, Hadassah Braun School of Public Health and Community Medicine, Hebrew University, Jerusalem 9112102, Israel.
Ibrahim Nasser EddinHadassah Medical Center, Jerusalem 9112102, Israel.
Karen Olshtain-PopsHadassah Medical Center, Jerusalem 9112102, Israel.
Daniel ElbirtFaculty of Medicine, Hadassah Braun School of Public Health and Community Medicine, Hebrew University, Jerusalem 9112102, Israel.ORCID 0000-0002-9056-236X
Rozalia SmolyakovGoldman Medical School, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba 8410501, Israel.
Valery IstominHillel Yaffe Medical Center, Hadera 38100, Israel.
Marina WaxNational HIV-1 and Viral Hepatitis Reference Laboratory, Chaim Sheba Medical Center, Ramat Gan 5262112, Israel.
Yael GozlanNational HIV-1 and Viral Hepatitis Reference Laboratory, Chaim Sheba Medical Center, Ramat Gan 5262112, Israel.
Orna MorFaculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0003-3207-4226

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Israel, irregular migrants (IMs) living with human immunodeficiency virus (HIV-1) that have no access to regular health insurance are provided with HIV-1-related health coverage under a public-private partnership (PPP) program initiated by the Ministry of Health in 2014. Here we characterized IMs referred to the PPP in 2019-2024 and used a linear mixed-effects model to follow up their CD4 and HIV-1 viral load (VL) counts for a median period of 16 months. Subtypes, resistance mutations and phylogenetic relationships were determined in all cases with viral failure and in selected cases with available blood remains. A total of 231 of 238 referred to the PPP initiated antiretroviral treatment (ART) with nucleoside reverse transcriptase inhibitors (NRTIs) and either non-nucleoside reverse transcriptase inhibitors (NNRTIs, 61.5%, 142/231) or protease inhibitors (PIs, 38.5%, 89/231). Irrespective of the treatment regimen, all these individuals increased their CD4 and decreased their VL trajectories over time (

Indexed as

Anti-HIV AgentsHealth Services AccessibilityHIV-1HIV InfectionsTransients and MigrantsAdultCD4 Lymphocyte CountDrug Resistance, ViralFemaleHumansIsraelMaleMiddle AgedMutationPhylogenyViral LoadAnti-HIV AgentsCD4 and viral load (VL) trajectoriesHIV-1 (human immunodeficiency virus)irregular migrants (IMs)Israelministry of health (MOH)public–private partnership (PPP) program

Identifiers

PMID41472237
PMCPMC12737707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.